Skip to main content

Table 3 List of HDACs and their current status in clinical trials

From: The quest for an effective and safe personalized cell therapy using epigenetic tools

Group

Example

Current status

Short-chain fatty acid

Valproic acid

Phase II CT

Phenyl butyrate

Phase II CT

Pivanex

Phase II CT

Hydroxamic acids

Vorinostat

FDA approved

Panobinostat

Phase III CT

Belinostat

Phase II CT

Abexinostat

Phase II CT

Resminostat

Phase II CT

Givinostat

Phase II CT

Dacinostat

Phase II CT

Pracinostat

Phase II CT

Cyclic tetrapeptide

Romidepsin

FDA approved

Apicidin

Phase II CT

Trapoxin A

No data

Benzamide

Mocetinostat

Phase II CT

Entinostat

Phase II CT

Rocilinostat

Phase II CT